Page 41 - Viral Vector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Here's what the World Health Organisation WHO) has to say on the issue of "Adverse events following immunization (AEFI)" for any vaccine: "As vaccine-preventable infectious diseases continue to decline, people have become increasingly concerned about the risks associated with vaccines. Furthermore, technological advances and continuously increased knowledge about vaccines have led to investigations focused on the safety of existing vaccines which have sometimes created a climate of concern. "Adverse event following immunization is any untoward medical occurrence which follows immunization an...

The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m (€725m) in cash.

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots? The unchecked advance of the coronavirus disease 2019 (COVID-19) has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An encouraging new preprint, that appeared on the bioRxiv* server shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies. A host of candidat...

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2 A recent study conducted at the University of Malta Medical School, Malta, has revealed that a drop in the level of particulate matter 2.5 (PM2.5), which are airborne pollutant particles with a diameter of 2.5 micrometers, in the atmosphere due to lockdown is associated with the arrival of a newer variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has eventually displaced the original virus after lockdown. The new viral variant (D614G mutant) may be able to use other types of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) ... CytoDel IncJanuary 7, 2021 GMT Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection Supports the Development of New Approaches to Treat Multiple Neurological Diseases NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytoDel, Inc. (“CytoDel” or “the Company”), a privately-held corporation, today announces...